ClinicalTrials.gg
Not yet recruitingNCT07356271Updated Feb 17, 2026

Effects of Mouthwashes on the Oral Microbiome and Systemic Health

An Early Phase 1 interventional study of Use of mouthwashes in Hypertension, sponsored by University of Plymouth. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of Plymouth · Early Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

OVERVIEW

While antimicrobial mouthwashes are proven to be clinically effective for management of certain oral microbial diseases, recent studies suggest tha, in addition to targeting bacteria responsible for gum diseases such as gingivitis and periodontitis, they may harm healthy bacteria and disturb the balance and protective role of the oral microbiome (dysbiosis).

Most findings on the oral microbiome and mouthwashes involve chlorhexidine use, demonstrating that it may induce dysbiosis and compromise the host oral microenvironment . A recent study completed in 2025 has shown that CPC mouthwash can also inhibit nitrate synthesis in the mouth. However there remains a need for further research on other agents used in mouthrinses, such as hydrogen peroxide, essential oils, to determine whether their clinical effectiveness in managing oral disease is accompanied by changes to the oral microbiome. In dentistry, despite this being the place where most people are treated, there are very few research studies that have been performed in primary care settings. Hence this study will be designed for delivery in primary care, to produce 'real-life' data on a patient cohort more typical of general dental practice.

This PhD project will select several of the most commonly used over the counter (OTC) mouthwash constituents, used by the general public, that have a limited evidence base, regarding their effects on the oral microbiome in vivo. . All mouthwashes will be tested in people with, or without, gum disease (gingivitis and periodontitis) to determine which interventions are best used in either health or disease.

Read the detailed description

PROJECT AIMS

The aim of this project is to determine the role of different mouthwashes on the oral microbiome and its relationship with cardiovascular health. We will achieve this by conducting a double-blinded randomised clinical trial (pilot study) in a primary care dental setting, to investigate (i) the composition of the oral microbiome in different oral niches in periodontal health and disease, and (ii) determine how the oral microbiome is altered by the use of different mouthwashes during oral health and disease, with either , essential oil (EOs), CPCs, hydrogen peroxide (H2O2); all versus placebo (water or saline).

OVERVIEW

While antimicrobial mouthwashes are proven to be clinically effective for management of certain oral microbial diseases, recent studies suggest that, in addition to targeting bacteria responsible for gum diseases such as gingivitis and periodontitis, they may harm healthy bacteria and disturb the balance and protective role of the oral microbiome (dysbiosis).

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Oral microbiome dysbiosis
03

In context

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Plymouth is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • Inclusion \& Exclusion

All individuals aged 18 years and older will be eligible to take part in this study. Exclusion will apply to individuals who:

Are current smokers, due to the well-documented impact of smoking on oral and systemic health.

Have a known diagnosis of hypertension, diabetes, or cancer, as these systemic conditions may influence oral microbiome and inflammatory responses.

Have taken a course of antibiotics within the last three months, since antibiotics are known to disrupt microbial balance and may confound the interpretation of oral microbiome data.

Report allergies to essential oils or to milk proteins, as these ingredients may be present in the study mouthwash and could trigger adverse reactions.

In addition, participants who have never previously used a mouthwash will be excluded. This is a precautionary measure designed to avoid even the minimal possibility of adverse responses.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    mouthwashes

    Population This study aims to recruit up to 200 participants over a period of thr years on a part-time basis. Recruitment will be carried out through three sites: (i) the University of Plymouth campus population (as successfully used in earlier studies such as Bescos et al., 2020), (ii) the Peninsula Dental School / Peninsula Dental Social Enterprise (PDSE) triage patient clinics (non-NHS clinics), and (iii) the Southside Dental Practice, a private primary care practice located in Southsea, Portsmouth. Sample size was calculated using G\*Power software, which showed that usually 20-30 participants per group are enough, depending on whether the focus is clinical outcomes, blood markers, or microbiome changes. For this project, the main outcome is clinical effectiveness, measured through changes in plaque and bleeding scores. The PDSE clinics collectively see around 400 patients per day across their sites, providing a large and diverse pool of potential participants. In comparis

    Drug: Use of mouthwashes

  • Experimental
    placebo

    Population This study aims to recruit up to 200 participants over a period of 3 years on a part-time basis. Recruitment will be carried out through three sites: (i) the University of Plymouth campus population (as successfully used in earlier studies such as Bescos et al., 2020), (ii) the Peninsula Dental School / Peninsula Dental Social Enterprise (PDSE) triage patient clinics (non-NHS clinics), and (iii) the Southside Dental Practice, a private primary care practice located in Southsea, Portsmouth. Sample size was calculated using G\*Power software, which showed that usually 20-30 participants per group are enough, depending on whether the focus is clinical outcomes, blood markers, or microbiome changes. For this project, the main outcome is clinical effectiveness, measured through changes in plaque and bleeding scores. The PDSE clinics collectively see around 400 patients per day across their sites, providing a large and diverse pool of potential participants. In comparis

    Drug: Use of mouthwashes

Interventions

  • DrugUse of mouthwashes

    Population This study aims to recruit up to 200 participants over a period of 3 years on a part-time basis. Recruitment will be carried out through three sites: (i) the University of Plymouth campus population (as successfully used in earlier studies such as Bescos et al., 2020), (ii) the Peninsula Dental School / Peninsula Dental Social Enterprise (PDSE) triage patient clinics (non-NHS clinics), and (iii) the Southside Dental Practice, a private primary care practice located in Southsea, Portsmouth. Sample size was calculated using G\*Power software, which showed that usually 20-30 participants per group are enough, depending on whether the focus is clinical outcomes, blood markers, or microbiome changes. For this project, the main outcome is clinical effectiveness, measured through changes in plaque and bleeding scores. The PDSE clinics collectively see around 400 patients per day across their sites, providing a large and diverse pool of potential participants. In compariso

06

What researchers measure

Primary outcomes

  1. effect of mouthwashes on oral microbiome

    EXPECTED OUTCOMES / DELIVERABLES One of the main expected outcomes of this study is to provide clear evidence on the clinical effectiveness of commonly used mouthwashes and their effect on oral microbiome and cardiovascular health. It is anticipated that some mouthwashes will significantly reduce dental plaque and bleeding on probing when compared with placebo. Demonstrating these effects will help confirm which products can genuinely support daily oral hygiene and clinical treatment of gum conditions, alongside either beneficial or no effects on the oral microbiome, such that their beneficial effects do not outweigh the risks. In participants with good oral health, we thus expect that effective mouthwashes will not only reduce plaque but also maintain a balanced oral microbiome. This means that mouthwashes should support microbiome health, without causing dysbiosis or loss of diversity. In participants with gingivitis or periodontal disease, the expectation is that mouthwash

    Time frame: three years

Secondary outcomes

  1. effect of mouthwashes on cardiovascular health

    EXPECTED OUTCOMES / DELIVERABLES One of the main expected outcomes of this study is to provide clear evidence on the clinical effectiveness of commonly used mouthwashes and their effect on oral microbiome and cardiovascular health. It is anticipated that some mouthwashes will significantly reduce dental plaque and bleeding on probing when compared with placebo. Demonstrating these effects will help confirm which products can genuinely support daily oral hygiene and clinical treatment of gum conditions, alongside either beneficial or no effects on the oral microbiome, such that their beneficial effects do not outweigh the risks. In participants with good oral health, we thus expect that effective mouthwashes will not only reduce plaque but also maintain a balanced oral microbiome. This means that mouthwashes should support microbiome health, without causing dysbiosis or loss of diversity. In participants with gingivitis or periodontal disease, the expectation is that mouthwash

    Time frame: three years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • References Al-Maweri, S. A., et al. (2025). "The association between the oral microbiome and hypertension: a systematic review." Journal of oral microbiology 17(1): 2459919. Alrashdan, M. S., et al. (2023). "The Effects of Antimicrobial Mouthwashes on Systemic Disease: What Is the Evidence?" International dental journal 73: S82-S88 Aravinth, V., et al. "Comparative evaluation of saltwater rinse with chlorhexidine against oral microbes: a school-based randomized controlled trial " Indian Soc Pedod Prev Dent, 35 (4) (2017), pp. 319-326 Bescos, R., et al. "The comparative effect of propolis and chlorhexidine mouthwash on oral nitrite-producing bacteria and blood pressure regulation." Bescos, R., et al. (2020). "Effects of Chlorhexidine mouthwash on the oral microbiome." Sci Rep 10(1): 5254-5254. Bondonno, C. P., et al. (2015). "Antibacterial Mouthwash Blunts Oral Nitrate Reduction and Increases Blood Pressure in Treated Hypertensive Men and Women." Am J Hypertens 28(5): 572-575. Brookes, Z., et al. (2023). "Antimicrobial Mouthwashes: An Overview of Mechanisms-What Do We Still Need to Know?" International dental journal. Brookes, Z., et al. (2023). "Mouthwash Effects on the Oral Microbiome: Are They Good, Bad, or Balanced?" International dental journal. Burcham, Z. M., et al. (2020). "Patterns of Oral Microbiota Diversity in Adults and Children: A Crowdsourced Population Study." Scientific reports 10(1): 2133. Burton, J. P., et al. (2006). "preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters." Journal of Applied Microbiology 100(4): 754-764. Casarin, M., et al. (2023). "Effect of mouthwashes on gingival healing after surgical procedures: A systematic review." European Journal of Oral Sciences 131(3): e12931-n/a. Caselli, E., et al. (2020). "Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture." BMC Microbiol 20(1): 120-120

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2028, 24 months later.

Of 44 non-industry phase 1 interventional studies under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's planned 24 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 21, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Mar 1, 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07356271
Lead sponsor
University of Plymouth
Responsible party
Mimoza Cana-Bishop (Mrs, University of Plymouth) — Principal investigator
First posted
Jan 21, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

mimoza cana-bishop, MSc
Contact
mimoza.cana-bishop@plymouth.ac.uk
+447903995399
Zoe Brookes, PhD
Contact
zoe.brookes@plymouth.ac.uk
441752586828
zoe Brookes, PhD
study director · University of Plymouth

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion